TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)

Historical Holders from Q3 2021 to Q4 2025

Type / Class
Equity / Voting Common Stock, par value $0.0001 per share
Symbol
TCRX on Nasdaq
Shares outstanding
52,382,313
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
34,601,160
Holdings value
$62,910,264
% of all portfolios
0%
Share change
-1,129,874
Value change
-$1,894,620
Average buys %
+0%
Average sells %
-0%
Number of holders
72
Price from insider filings
$0.8989
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 15% +37% $14,143,225 +$4,500,000 7,857,347 +47% Lynx1 Capital Management LP 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 10% $6,684,697 5,263,541 BVF PARTNERS L P/IL 31 Mar 2025
K2 HealthVentures Equity Trust LLC 6.9% $4,575,429 3,602,700 K2 HealthVentures Equity Trust LLC 31 Dec 2024
ADAGE CAPITAL PARTNERS GP, L.L.C. 7.1% $4,445,000 3,500,000 Adage Capital Management, L.P. 31 Dec 2024
Adage Capital Management, L.P. 2.5% $1,957,500 1,350,000 Adage Capital Management, L.P. 30 Jun 2025
BlackRock, Inc. 1.8% -72% $1,274,636 -$2,483,708 958,373 -66% BlackRock, Inc. 30 Jun 2025
EcoR1 Capital, LLC 1.3% $841,798 662,833 EcoR1 Capital, LLC 31 Mar 2025
As of 30 Sep 2025, TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) has 72 institutional shareholders filing 13F forms. They hold 34,601,160 shares of 52,382,313 outstanding shares (66%) .

Top 25 institutional shareholders own 63% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 15% 7,857,347 0% 2.9% $14,300,372
BVF INC/IL 10% 5,226,074 0% 0.39% $9,511,455
BAKER BROS. ADVISORS LP 5.3% 2,784,792 0% 0.04% $5,068,321
BlackRock, Inc. 4.5% 2,382,764 -7.2% 0% $4,336,629
VANGUARD GROUP INC 4.4% 2,317,916 +7.8% 0% $4,218,607
Propel Bio Management, LLC 3.7% 1,932,304 -7.4% 3.5% $3,516,793
Aberdeen Group plc 2.6% 1,354,820 +52% 0% $2,465,772
Deer Management Co. LLC 2.4% 1,245,504 0% 0.2% $2,266,817
Alphabet Inc. 2.1% 1,077,080 0% 0.08% $1,960,286
Simplify Asset Management Inc. 1.7% 904,972 -14% 0.03% $1,647,049
MORGAN STANLEY 1.6% 847,537 -0.68% 0% $1,542,518
RENAISSANCE TECHNOLOGIES LLC 1.6% 829,919 +4.8% 0% $1,510,453
DC Funds, LP 1.2% 630,000 0% 37% $1,146,600
TANG CAPITAL MANAGEMENT LLC 1.1% 600,000 0% 0.04% $1,092,000
GEODE CAPITAL MANAGEMENT, LLC 1.1% 567,657 +0.23% 0% $1,033,532
MILLENNIUM MANAGEMENT LLC 0.89% 466,086 -26% 0% $848,277
TWO SIGMA INVESTMENTS, LP 0.8% 419,404 +15% 0% $763,315
CITADEL ADVISORS LLC 0.75% 390,747 +78% 0% $711,160
TWO SIGMA ADVISERS, LP 0.55% 288,800 +35% 0% $525,616
JPMORGAN CHASE & CO 0.45% 237,750 -17% 0% $432,705
BANK OF AMERICA CORP /DE/ 0.43% 223,024 +2.3% 0% $405,903
STATE STREET CORP 0.38% 197,313 -1.6% 0% $359,110
BROWN BROTHERS HARRIMAN & CO 0.27% 143,051 0% 0% $260,353
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.27% 140,400 -8.7% 0.01% $255,528
GOLDMAN SACHS GROUP INC 0.25% 130,980 -70% 0% $238,383

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 0 $0 -$17 0
2025 Q3 34,601,160 $62,910,264 -$1,894,620 $1.82 72
2025 Q2 35,724,879 $51,820,655 -$5,881,536 $1.45 79
2025 Q1 40,135,840 $55,390,189 -$2,855,485 $1.38 92
2024 Q4 41,512,999 $126,202,372 -$5,946,742 $3.04 87
2024 Q3 41,835,445 $208,343,784 +$255,932 $4.98 86
2024 Q2 41,438,662 $242,462,174 +$40,505,809 $5.85 78
2024 Q1 34,291,369 $272,339,183 +$19,165,614 $7.94 65
2023 Q4 31,912,819 $186,051,442 +$7,357,775 $5.83 54
2023 Q3 28,588,231 $73,195,868 +$2,177,864 $2.56 32
2023 Q2 27,951,619 $69,879,871 +$45,817,227 $2.50 28
2023 Q1 9,651,730 $20,268,564 +$609,616 $2.10 27
2022 Q4 9,519,305 $14,788,379 -$121,392 $1.55 28
2022 Q3 9,508,092 $29,003,732 -$530,732 $3.05 24
2022 Q2 9,682,082 $30,449,817 +$1,526,723 $3.14 23
2022 Q1 9,368,530 $26,232,000 -$1,531,305 $2.80 23
2021 Q4 9,861,945 $44,380,000 -$2,457,430 $4.50 28
2021 Q3 10,134,939 $83,484,000 +$83,484,012 $8.34 26